Skip to main content

Aurinia Pharm Ord(AUPH-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Volume

Latest News

Aurinia Presents Results from the Two-Year AURORA 2 Continuation Study at the 2022 European Renal Association (ERA) Congress
Business Wire - Fri May 20, 11:07AM CDT
Business Wire
Fri May 20, 11:07AM CDT
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, today presented for the first time the results of the AURORA 2...
Aurinia Pharmaceuticals Announces Presentations at the 2022 ERA Congress and the 2022 EULAR Congress
Business Wire - Mon May 16, 6:17AM CDT
Business Wire
Mon May 16, 6:17AM CDT
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, today announced that data from multiple studies of LUPKYNIS™...
INVESTOR DEADLINE: Aurinia Pharmaceuticals Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – AUPH
Business Wire - Fri May 13, 6:15PM CDT
Business Wire
Fri May 13, 6:15PM CDT
The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) securities between May 7, 2021 and February 25, 2022, both dates inclusive (the “Class Period”) have...
Aurinia Reports First Quarter 2022 Financial and Operational Results
Business Wire - Tue May 10, 5:00AM CDT
Business Wire
Tue May 10, 5:00AM CDT
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the first quarter ended March 31, 2022. Amounts, unless specified otherwise, are expressed in U.S. dollars.
Notice of New Dial-In Numbers for Aurinia Pharmaceuticals First Quarter 2022 Financial and Operational Results on May 10, 2022
Business Wire - Fri May 6, 3:05PM CDT
Business Wire
Fri May 6, 3:05PM CDT
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) announces a change to the dial-in number(s) for the upcoming first quarter financial and operational results announcement on Tuesday, May 10, 2022. The new numbers for...
Aurinia Pharmaceuticals to Release First Quarter 2022 Financial and Operational Results on May 10, 2022
Business Wire - Mon May 2, 3:05PM CDT
Business Wire
Mon May 2, 3:05PM CDT
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced that it will release financial and operational results for first quarter 2022 on Tuesday, May 10, 2022, before markets open. Aurinia’s management team will...
3 Healthcare Companies With Revenue Spiking 100% or More
Motley Fool - Mon May 2, 3:00PM CDT
Motley Fool
Mon May 2, 3:00PM CDT
Here's why three Fool.com contributors are bullish on Outset Medical, Aurinia Pharmaceuticals, and Shockwave Medical.
AUPH Stock News: Robbins LLP Investigates Aurinia Pharmaceuticals Inc. (AUPH) on Behalf of Shareholders
Business Wire - Tue Apr 26, 12:37PM CDT
Business Wire
Tue Apr 26, 12:37PM CDT
Shareholder rights law firm Robbins LLP is investigating Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) and its officers and directors to determine whether they breached their fiduciary duties and violated securities laws regarding the financial...
DEADLINE: Aurinia Pharmaceuticals Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – AUPH
Business Wire - Fri Apr 22, 5:30PM CDT
Business Wire
Fri Apr 22, 5:30PM CDT
The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) securities between May 7, 2021 and February 25, 2022, inclusive (the “Class Period”) have until June 14,...
Bronstein, Gewirtz & Grossman, LLC Notifies Aurinia Pharmaceuticals Inc. (AUPH) Investors of Class Action and Encourages Investors to Contact the Firm
Business Wire - Thu Apr 21, 10:00AM CDT
Business Wire
Thu Apr 21, 10:00AM CDT
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Aurinia Pharmaceuticals Inc. (“Aurinia” or the “Company”) (NASDAQ: AUPH) and certain of its officers, on behalf of...